Influence of Paclitaxel and Nedaplatin concurrent late course accelerated hyperfractionated radiotherapy combined with high-frequency hyperthermia in vitro on curative effect and survival rate of patients with locally advanced esophageal cancer
LIU Lihua1 CAI Jundong1 LIU Yanqin2 ZHENG Yumei1 WANG Haisheng3 DING Baiying1 LI Xiaodong1 LIU Jing4 QIAO Weichao1 DONG Xinhong1
1.Chengde Tumour Hospital, Hebei Province, Chengde 067000, China;
2.Longhua County Hospital of Traditional Chinese Medicine, Hebei Province, Chengde 067000, China;
3.Chengde County East White Flag Township Health Center, Hebei Province, Chengde 067000, China;
4.Chengde Maternal and Child Health-Care Hospital, Hebei Province, Chengde 067000, China
Abstract:Objective To explore the influence of Paclitaxel and Nedaplatin concurrent late course accelerated hyperfractionated radiotherapy combined with high frequency hyperthermia in vitro on curative effect and survival rate of patients with locally advanced esophageal cancer. Methods From August 2011 to July 2012, in Chengde Tumour Hospital, 144 patients with locally advanced esophageal cancer were selected, and they were divided into control group (72 cases) and observation group (72 cases) according to the random number table method. The control group was treated with Paclitaxel and Nedaplatin concurrent late course accelerated hyperfractionated radiotherapy, and the observation group was given ombined with hyperthermia in vitro on the basis of the control group. The rapeutic effect and survival rate in the two groups were contrasted, and toxic and side effects in the two groups were observed. Results The total effective rate of the combination group (86.11%) was significantly higher than that of the control group (62.50%), the difference was statistically significant (P < 0.05). The side effects during the treatment occured in two groups, two groups were compared, the difference was not statistically significant (P > 0.05). Survival rates of 1, 2, 3, 4 years in the observation group (70.83%, 55.56%, 45.83%, 38.89%) were significantly higher than those in the control group (55.56%, 40.27%, 29.17%, 22.22%), the differences were statistically significant (P < 0.05). Conclusion The effect is better of Paclitaxel and Nedaplatin concurrent late course accelerated hyperfractionated radiotherapy combined with hyperthermia in vitro on patients with locally advanced esophageal cancer, with high survival rate. It has a certain promotion value.
刘丽华1 蔡君东1 刘艳琴2 郑玉妹1 王海生3 丁柏英1 李晓东1 刘晶4 乔炜超1 董新红1. 紫杉醇、奈达铂同步后程加速超分割放疗联合体外高频热疗对局部晚期食管癌的影响[J]. 中国医药导报, 2017, 14(23): 80-83.
LIU Lihua1 CAI Jundong1 LIU Yanqin2 ZHENG Yumei1 WANG Haisheng3 DING Baiying1 LI Xiaodong1 LIU Jing4 QIAO Weichao1 DONG Xinhong1. Influence of Paclitaxel and Nedaplatin concurrent late course accelerated hyperfractionated radiotherapy combined with high-frequency hyperthermia in vitro on curative effect and survival rate of patients with locally advanced esophageal cancer. 中国医药导报, 2017, 14(23): 80-83.